Pharmaceutical Technology® spoke with Jeff Clement, executive director of Technical Sales for Development and Manufacturing Group at PCI Pharma Services, about the challenges and benefits of incorporating robotics into aseptic manufacturing.
Using robotics in sterile fill/finish operations provides “hands-off” aseptic manufacturing, says Jeff Clement, executive director of Technical Sales for Development and Manufacturing Group at PCI Pharma Services, in an interview with Pharmaceutical Technology® “Most of the robotic instruments don't even have a glove board. So, there's no human interaction with the equipment, which is great for contamination. You know, one source of contamination for a RABs [restricted access barriers] type of line would be the human operators, and with a robotic manufacturing system that takes that completely out of the equation.”
Companies already performing aseptic fill/finish are doing environmental monitoring and therefore have ISO 5 suites, according to Clement. “But with an isolator technology or a robotic system, which would incorporate isolator technology, basically, you can do that in an ISO 7 suite. So, actually, your classification is a little bit lower, so your environmental monitoring is lower. And basically, you can validate that the lower classification, which could be a quicker way to put in aseptic manufacturing.”
When adding robotic isolator technology to a new facility, modular systems are available that would require supporting services, such as HVAC systems, says Clement, “but with the lower classification required for your operating space for isolator and robotic technology,” he adds. “A lot of times, you can do that a little bit quicker and more economically than perhaps you could in the past [in comparison to] setting up a RAB system in an ISO 5 environment.”
PCI Pharma Services will be showcasing its products and services at the 2024 BIO International Convention in San Diego, Calif., from June 3–6.
FDA Approves Novartis Oral Treatment for Adults with C3 Glomerulopathy
March 25th 2025Fabhalta (iptacopan) received a positive opinion for treatment of C3G from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and has been approved twice before by FDA.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.